Malaysian Genomics Resource Centre Bhd 2025 AR2
The report highlights Malaysian Genomics Resource Centre Berhad's (MGRC) financial and sustainability performance for the fiscal year 2025. The company recorded a 45% increase in revenue to RM8.02 million, driven by stronger demand for its immunotherapy and cell therapy offerings. On the sustainability front, MGRC marked its third consecutive year of adopting the GRI Standards and began formalizing its greenhouse gas emissions inventory, reporting 293 tonnes of Scope 2 emissions. The company also maintained a diverse workforce with 79% female representation and achieved zero work-related injuries or fatalities during the year.
Company: Malaysian Genomics Resource Centre Bhd
Sector: Professional & technical services
Country: Malaysia
Year: 2025
Type: AR2
Pages: 136
Malaysian Genomics Resource Centre Bhd
The report highlights Malaysian Genomics Resource Centre Berhad's (MGRC) financial and sustainability performance for the fiscal year 2025. The company recorded a 45% increase in revenue to RM8.02 million, driven by stronger demand for its immunotherapy and cell therapy offerings. On the sustainability front, MGRC marked its third consecutive year of adopting the GRI Standards and began formalizing its greenhouse gas emissions inventory, reporting 293 tonnes of Scope 2 emissions. The company also maintained a diverse workforce with 79% female representation and achieved zero work-related injuries or fatalities during the year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees